CRO Company Adds Anatomic Pathology Testing Services to Serve China’s Pharma and Biotech Industries
Quintiles announced that its Beijing medical laboratory will offer an enhanced menu of anatomic pathology testing services to the Chinese biopharmaceutical industry. With this action, global CRO (clinical research organization) giant Quintiles is responding to the increasing sophistication of the pharmaceutical industry in the world’s most populous country.
Quintiles says the new service will help biopharma firms develop more effective cancer treatments. The lab also offers pathology assay development, digital pathology, and core lab test offerings that help customers comply with China’s restrictions on tissue import/export.